How to Get Rezdiffra (Resmetirom) in Vermont

What Is Rezdiffra and Why Does It Matter for Vermont Patients?

Rezdiffra (resmetirom) is the first FDA-approved medication specifically targeting metabolic dysfunction-associated steatohepatitis (MASH), formerly called non-alcoholic steatohepatitis (NASH). The FDA granted approval in March 2024 based on the MAESTRO-NASH phase 3 trial, which enrolled 966 patients with biopsy-confirmed MASH and fibrosis stages F1B through F3.

Vermont has an estimated adult MASH prevalence that mirrors national figures. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), roughly 3% to 5% of U.S. adults have NASH/MASH, and fibrosis progression occurs in a meaningful subset. For Vermonters previously limited to lifestyle modification or off-label therapies, resmetirom offers a targeted pharmacologic option. The drug works as a selective thyroid hormone receptor beta (THR-β) agonist, reducing hepatic fat and inflammation without the systemic thyroid effects seen with non-selective thyroid analogs [1]. The FDA prescribing label specifies that treatment is indicated for adults with MASH and moderate-to-advanced fibrosis (F2 or F3), confirmed by liver biopsy or validated noninvasive testing.

Eligibility Criteria: Who Qualifies in Vermont?

Before pursuing a prescription, Vermont patients should understand the clinical eligibility requirements. Rezdiffra is approved for adults with MASH and fibrosis stage F2 or F3. Cirrhotic patients (F4) are excluded from the current indication.

Diagnosis typically requires either a liver biopsy showing a NAFLD Activity Score (NAS) of 4 or higher with at least 1 point in each component (steatosis, lobular inflammation, ballooning), or validated noninvasive markers. The American Association for the Study of Liver Diseases (AASLD) guidelines recognize FibroScan (vibration-controlled transient elastography) with liver stiffness measurement (LSM) between 8.0 and 13.9 kPa as consistent with F2/F3 fibrosis. The Enhanced Liver Fibrosis (ELF) test and FIB-4 index also support staging [2]. A 2023 meta-analysis in Hepatology confirmed that combining FIB-4 with elastography improves diagnostic accuracy for identifying patients who benefit from pharmacotherapy.

Weight-based dosing applies: patients weighing <100 kg receive 80 mg once daily, while those ≥100 kg receive 100 mg once daily, as specified in the Rezdiffra prescribing information.

How to Get a Rezdiffra Prescription in Vermont

Getting the prescription involves three steps. First, confirm your diagnosis. Second, find a qualified prescriber. Third, manage prior authorization if your insurer requires it.

Step 1: Confirm MASH and fibrosis stage. Your provider will order baseline imaging (FibroScan or MR elastography) and blood-based fibrosis markers. A liver biopsy remains the gold standard per AASLD 2023 practice guidance, but noninvasive testing is increasingly accepted for treatment decisions.

Step 2: Find a prescriber. In Vermont, licensed MDs, DOs, NPs with full practice authority, and PAs with supervising physician agreements can all prescribe Rezdiffra. Hepatologists and gastroenterologists are the most common prescribers, though endocrinologists managing metabolic syndrome may also initiate therapy. The University of Vermont Medical Center's hepatology division and Dartmouth-Hitchcock (serving the Upper Valley region) both have liver disease programs familiar with resmetirom.

Step 3: Submit for prior authorization. Most commercial plans and Vermont Medicaid require PA. Begin the paperwork early. The typical turnaround is 5 to 14 business days.

Telehealth Access to Rezdiffra in Vermont

Vermont law permits telehealth prescribing of Rezdiffra. This matters for patients in rural areas. Telehealth providers licensed in Vermont can evaluate MASH patients, review imaging and lab results, and write prescriptions electronically.

The Vermont Board of Medical Practice requires that telehealth prescribers establish a legitimate provider-patient relationship, which can occur via synchronous video visit. Vermont enacted permanent telehealth parity legislation (Act 6, 2021), meaning insurers must cover telehealth visits at the same rate as in-person appointments. A study published in Hepatology Communications found that telehealth-based liver disease management achieved comparable adherence rates and clinical outcomes to in-person care, supporting its use for conditions like MASH.

HealthRX offers telehealth consultations with providers licensed in Vermont who specialize in metabolic liver disease. After reviewing your labs and imaging, a provider can prescribe Rezdiffra and coordinate pharmacy fulfillment without requiring an in-person visit.

Required Labs Before Starting Rezdiffra in Vermont

Your prescriber will order a specific panel of baseline labs before writing the prescription. These are not optional.

Liver function tests (LFTs): ALT, AST, alkaline phosphatase, total bilirubin, and albumin. The MAESTRO-NASH trial used ALT reduction as a key secondary endpoint, with the 80 mg group achieving a 22% mean reduction in ALT versus a 9% increase in the placebo arm at 52 weeks [1]. Baseline values establish your monitoring trajectory.

Thyroid function panel: TSH, free T4, and free T3. Because resmetirom is a THR-β agonist, monitoring thyroid axis activity is required. The FDA label mandates thyroid function assessment before initiation and periodically during treatment.

Lipid panel: Total cholesterol, LDL-C, HDL-C, and triglycerides. Resmetirom produced significant LDL-C reductions (a mean decrease of 13.6% at 80 mg) in MAESTRO-NASH, a finding consistent with THR-β-mediated upregulation of hepatic LDL receptors [1]. A post hoc analysis reported in the Journal of Hepatology showed that the lipid-lowering effect persisted through 52 weeks and was additive with background statin use.

Additional labs: CBC, INR, creatinine, and HbA1c are commonly ordered to assess overall metabolic status and rule out decompensated liver disease. Per the AACE 2023 consensus statement on MASH, HbA1c ≥5.7% flags concurrent insulin resistance that may influence treatment response.

Vermont Medicaid and Insurance Coverage

Vermont Medicaid covers Rezdiffra with prior authorization. This is significant because an estimated 23% of Vermont adults enrolled in Medicaid or the state's exchange plans have metabolic risk factors that overlap with MASH.

Prior authorization requirements typically include:

• Documented diagnosis of MASH via biopsy or validated noninvasive assessment
• Fibrosis staging confirming F2 or F3 (with specific elastography values or histologic scoring)
• Baseline lab results (LFTs, thyroid panel, lipid panel)
• Documentation that lifestyle modification (diet, exercise) was attempted or is ongoing
• Prescriber specialty or consultation note from hepatology/gastroenterology

Commercial insurers in Vermont, including Blue Cross Blue Shield of Vermont and MVP Health Care, have individual PA criteria. The Centers for Medicare & Medicaid Services (CMS) has not issued a national coverage determination for resmetirom, so Medicare Part D coverage varies by plan formulary. Check with your Part D plan directly.

The list price for Rezdiffra is approximately $47,400 per year. Madrigal Pharmaceuticals offers a patient assistance program and copay card for commercially insured patients, which may reduce out-of-pocket costs to as low as $0 for eligible individuals.

Pharmacy Access and Fulfillment in Vermont

Rezdiffra is available through both retail specialty pharmacies and 503A compounding pharmacies licensed in Vermont. Most patients receive the drug via specialty pharmacy fulfillment, which includes clinical coordination and refill management.

503A pharmacies in Vermont are licensed by the Vermont Board of Pharmacy and may compound or dispense resmetirom when they hold the appropriate registrations. These pharmacies can ship within the state, providing access to patients in rural areas where specialty pharmacies have limited brick-and-mortar presence.

Typical fulfillment timelines after PA approval:

• Specialty pharmacy (retail): 3 to 7 business days for initial fill
• Specialty pharmacy (mail order): 5 to 10 business days
• 503A compounding pharmacy: 5 to 10 business days, depending on sourcing

A 2024 survey in the American Journal of Health-System Pharmacy found that specialty pharmacy coordination reduced time-to-first-fill by a median of 4 days compared to traditional pharmacy pathways for newly approved hepatology drugs.

Clinical Efficacy: What the MAESTRO-NASH Data Show

The MAESTRO-NASH trial (N=966) is the registration study supporting Rezdiffra's approval. Key findings at 52 weeks:

• MASH resolution without fibrosis worsening: 25.9% with resmetirom 80 mg vs. 9.7% with placebo (P<0.001)
• Fibrosis improvement by ≥1 stage without NASH worsening: 24.2% with 80 mg vs. 14.2% with placebo (P<0.001)
• LDL-C reduction: mean decrease of 13.6% at 80 mg
• ALT reduction: 22% mean decrease at 80 mg vs. 9% increase with placebo

The 100 mg dose showed numerically higher MASH resolution rates (29.9% vs. 9.7% placebo), with a similar safety profile [1]. The trial's 52-week biopsy-confirmed endpoints represent the first time any MASH drug demonstrated histologic improvement in a phase 3 setting, a finding that the New England Journal of Medicine editorial described as "a milestone for a disease without prior approved pharmacotherapy."

Ongoing extension data will evaluate durability beyond 52 weeks and impact on hard clinical endpoints (progression to cirrhosis, liver transplant, mortality).

Side Effects and Monitoring During Treatment

The most common adverse events in MAESTRO-NASH were gastrointestinal: diarrhea (27% at 100 mg vs. 16% placebo) and nausea (22% at 100 mg vs. 13% placebo), according to the FDA prescribing label. Most GI events were mild to moderate and decreased after the first 4 to 8 weeks of treatment.

Monitoring schedule recommended by the label and AASLD guidance:

• Thyroid function: Check TSH and free T4 at baseline, 4 to 8 weeks after initiation, and every 6 to 12 months thereafter
• LFTs: Repeat at 12 weeks, then every 6 months
• Lipid panel: Repeat at 12 weeks to assess LDL-C response

Resmetirom should be discontinued if ALT exceeds 5 times the upper limit of normal or if clinical signs of hepatotoxicity develop. Drug interactions are minimal; resmetirom is metabolized primarily by CYP3A4, and the FDA label notes that strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) should be avoided or used with dose adjustment.

Transferring a Rezdiffra Prescription to Vermont

Patients relocating to Vermont or seeking care from a Vermont-licensed provider can transfer an existing Rezdiffra prescription. Vermont accepts out-of-state prescriptions for FDA-approved medications under the Vermont Pharmacy Practice Act. The receiving pharmacy verifies prescriber credentials and may contact the original prescriber for confirmation.

For patients using specialty pharmacy mail-order services, transfer is often unnecessary if the dispensing pharmacy already ships to Vermont addresses. Confirm your specialty pharmacy's shipping coverage before initiating a formal transfer.

Patients switching insurers during a move should request a coverage determination from the new plan before the existing supply runs out. A 30-day bridge supply is typically available while PA processes at the new insurer.